Eckert & Ziegler BEBIG

Contributing to saving lives !

We are active in the health care sector and specialized on cancer treatment by radiation technology. Our specificity is to focus on cancer treatment by brachytherapy, using implants, plaques or catheters containing minuscule quantities of a radioisotope. So far, we have developed Iodine-125 implants against prostate cancer, Ruthenium-106 eye applicators and plaques for eye cancer treatment, and afterloaders using catheters for a number of different applications.

Eckert & Ziegler BEBIG is the result of the combination of two companies:
IBt s.a., a Belgian company founded in 1996 and Bebig GmbH, incorporated in 1992.

Milestones

• June 2011: Name change from IBt to Eckert & Ziegler BEBIG. The new name, Eckert & Ziegler BEBIG S.A., underlines the company's affiliation with the Eckert & Ziegler Group, one of the world's largest providers of isotope technology for medical, scientific, and industrial purposes.
• March 2010: Takeover bid process by Eckert & Ziegler AG, which now owns over 72% of Eckert & Ziegler BEBIG.
• June 2009: Joint venture in Russia
  Signature of two major contracts with NanoBrachyTech, a joint venture that focuses on the development of innovative nano technologies for the treatment of cancer by brachytherapy and on manufacturing of microsources and nanostructures for the delivery of medical treatment. IBt holds a 15% equity stake of this Joint venture.  
• April 2009: Mandatory Take Over imposed by CBFA on all IBt shares
  In accordance with European legislation, the CBFA (regulatory authority in Belgium) imposes on two of its shareholders (Eckert & Ziegler AG and SMI Steglitz Medinvest) to launch a mandatory take over bid on all IBt shares, type ‘B' beneficiary shares and on all outstanding IBt D warrants. The imposed price for the regular shares is 3.47 EUR/share. The price is to be paid either in cash or in shares of Eckert & Ziegler AG, or a combination thereof.
• November 2008: IBt Bebig grows and diversifies into Temporary Brachytherapy.
  Purchase of two products lines currently operated by subsidiaries of Eckert & Ziegler AG. Those two new businesses are focused on the treatment of Eye Cancer (Implants Plaques) and the treatment of Gynaecological Cancers (Temporary Implants)
• September 2008: IBt Bebig group expands in Spain
  The renowned Madrid cancer research center Hospital Universitario Ramón y Cajal has chosen IBt Bebig as its product supplier for radiotherapy products.
• August 2008: Incorporation of BEBIG SARL
• February 2008: Creation of the new market leader in Europe
  IBt s.a. and Bebig GmbH combine their activities to become the undisputed market leader in Europe in the field of permanent brachytherapy solutions.